Medical Marijuana Cut Migraine Frequency by More Than Half in 121 Patients

The Study

This wasn't a randomized trial. It was a retrospective chart review — the research equivalent of looking back at what already happened. Rhyne's team pulled medical records from 121 adults with a primary migraine diagnosis who had been recommended medical marijuana at two Colorado clinics between 2010 and 2014. Every patient had at least one follow-up visit documenting migraine frequency before and after starting cannabis.

The Breakdown

The results weren't uniform. Different patients used cannabis differently, and the outcomes varied accordingly.

The form of cannabis mattered. Patients who used inhaled cannabis (smoked or vaporized) reported better acute migraine relief — they could abort an attack in progress. Patients who used edibles reported more preventive benefit but also more side effects, particularly somnolence. Most patients ended up using both: daily edibles or oils for prevention, inhaled cannabis for acute attacks.

The Endocannabinoid Connection

Rhyne's findings are consistent with Ethan Russo's clinical endocannabinoid deficiency hypothesis. If migraine involves deficient endocannabinoid signaling — as suggested by CSF studies showing reduced anandamide in chronic migraineurs — then supplementing with plant cannabinoids should, in theory, help.

The serotonergic mechanism adds another layer. Cannabinoids modulate serotonin receptors in the central nervous system — the same target as triptans, the gold-standard acute migraine treatment. THC acts on 5-HT1A and 5-HT2A receptors, potentially affecting the same pathways that migraine drugs target through a different pharmacological route.

This isn't proof that cannabis works for migraine through endocannabinoid supplementation or serotonin modulation. But it's biological plausibility that makes the clinical observations harder to dismiss.

The Limitations — And They're Significant

The absence of a placebo group is the critical weakness. Chronic pain and migraine have notoriously high placebo response rates — 30% or more in some trials. Patients who actively seek cannabis treatment and believe it will help are precisely the population most likely to experience placebo benefit. The 55% reduction could be partly or largely placebo-driven.

But "partly placebo-driven" isn't "not real." Even if half the effect is placebo, a 25% real reduction in migraine frequency would still be clinically meaningful for patients who've exhausted other options.

What Happened Next

Rhyne's study launched a wave of migraine-cannabis research. Subsequent studies have generally confirmed the association:

• Larger surveys have replicated the self-reported benefit
• Laboratory studies have documented cannabinoid effects on trigeminovascular pathways
• The CECD framework has gained additional supporting evidence
• But as of 2026, no large randomized controlled trial of cannabis for migraine prevention has been published

This remains one of the most frustrating evidence gaps in cannabis medicine. Millions of migraine patients use cannabis. The biological plausibility is strong. The observational data is consistent. And yet the gold-standard evidence — a large, placebo-controlled RCT — doesn't exist.

For migraine patients considering cannabis, our guide on cannabis and migraines covers the full evidence landscape, including what to try, what to avoid, and how to talk to your neurologist about it.

Frequently Asked Questions

Does cannabis prevent migraines?

This retrospective study found a 55% reduction in monthly migraine frequency (10.4 to 4.6) in 121 patients using medical cannabis. However, this is observational data without a placebo group — the true effect size is likely smaller than 55% after accounting for placebo response and regression to the mean. No randomized trial has been published. The biological plausibility is strong (endocannabinoid system involvement in migraine pathways), but the clinical evidence remains preliminary. See our full guide on cannabis for migraine.

Should I smoke or eat cannabis for migraines?

This study found that inhaled cannabis worked better for aborting acute attacks (fast onset), while edibles worked better for daily prevention (sustained effect). Most patients used both. The tradeoffs: inhaled cannabis acts within minutes but carries respiratory risks; edibles are harder to dose but provide longer coverage. If considering cannabis for migraines, discuss with your healthcare provider and start with low doses.

Is this study reliable?

It's suggestive but not conclusive. A retrospective chart review at two clinics with 121 self-selected patients is a low tier of evidence. There's no placebo group, no randomization, and no blinding. The results are consistent with other observational data and with the known pharmacology — but they don't constitute proof. Randomized trials are needed and overdue.